Literature DB >> 832523

Bacteriological evaluation of fosfomycin in clinical studies.

A Rodríguez, A Gallego, T Olay, J M Mata.   

Abstract

Since fosfomycin has behaved in vitro as a broad-spectrum antibiotic, an attempt has been made to evaluate this behaviour in controlled clinical study carried out at different Spanish hospitals. A total of 959 patients were treated for some of the following infectious clinical processes: gonococcal urethritis, typhoid fever, enterocolitis, acute and chronic urinary tract infections, osteomyelitis, chronic otorrhoea, septicaemia, meningitis, peritonitis, surgical and suppurative infections, bronchitis, pneumonia, pharyngoamygdalitis, burns, endometritis, ocular infection, whooping cough and nasal carriers of S. aureus. The results obtained as a function of the microorganism isolated in these clinical processes in percentage of clinical and bacteriological success have been 96% of the S. aureus infections, 95% of the Streptococcus sp. including S. pneumoniae, 90% of the N. gonorrhoeae infections, 94% of the E. coli infections including enteropathogenic E. coli, 90% of the S. marcescens infections, 76% of the Proteus sp. infections, 72% of the Klebsiella-Enterobacter infections, 66% of P. aeruginosa infections and 78% of the S. typhi infections.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832523     DOI: 10.1159/000222055

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  11 in total

1.  Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria.

Authors:  P Arca; M Rico; A F Braña; C J Villar; C Hardisson; J E Suárez
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

2.  Cloning and molecular epidemiology of plasmid-determined fosfomycin resistance.

Authors:  C J Villar; C Hardisson; J E Suárez
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

3.  In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.

Authors:  S H Guenthner; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Fosfomycin trometamol: activity in vitro against urinary tract pathogens.

Authors:  D Greenwood
Journal:  Infection       Date:  1990       Impact factor: 3.553

5.  In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus.

Authors:  S Alvarez; M Jones; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

6.  Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.

Authors:  Sangeeta Sastry; Lloyd G Clarke; Hind Alrowais; Ashley M Querry; Kathleen A Shutt; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

7.  In vitro investigations with fosfomycin on Mueller-Hinton agar with and without glucose-6-phosphate.

Authors:  H Grimm
Journal:  Infection       Date:  1979       Impact factor: 3.553

8.  Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus.

Authors:  R Haag
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

Review 9.  A new strategy to fight antimicrobial resistance: the revival of old antibiotics.

Authors:  Nadim Cassir; Jean-Marc Rolain; Philippe Brouqui
Journal:  Front Microbiol       Date:  2014-10-20       Impact factor: 5.640

10.  Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.

Authors:  Ilya Nikolaevich Zykov; Ørjan Samuelsen; Lotte Jakobsen; Lars Småbrekke; Dan I Andersson; Arnfinn Sundsfjord; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.